These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 9574550

  • 1. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells.
    Toes RE, van der Voort EI, Schoenberger SP, Drijfhout JW, van Bloois L, Storm G, Kast WM, Offringa R, Melief CJ.
    J Immunol; 1998 May 01; 160(9):4449-56. PubMed ID: 9574550
    [Abstract] [Full Text] [Related]

  • 2. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors.
    Toes RE, Blom RJ, Offringa R, Kast WM, Melief CJ.
    J Immunol; 1996 May 15; 156(10):3911-8. PubMed ID: 8621930
    [Abstract] [Full Text] [Related]

  • 3. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts.
    Gabrilovich DI, Ciernik IF, Carbone DP.
    Cell Immunol; 1996 May 25; 170(1):101-10. PubMed ID: 8665590
    [Abstract] [Full Text] [Related]

  • 4. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    Wang J, Saffold S, Cao X, Krauss J, Chen W.
    J Immunol; 1998 Nov 15; 161(10):5516-24. PubMed ID: 9820528
    [Abstract] [Full Text] [Related]

  • 5. Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide.
    Oh ST, Kim CH, Park MY, Won EH, Sohn HJ, Cho HI, Kang WK, Hong YK, Kim TG.
    Vaccine; 2006 Apr 05; 24(15):2860-8. PubMed ID: 16443309
    [Abstract] [Full Text] [Related]

  • 6. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A, Chatterjee SK, Foon KA, Celis E, Bhattacharya-Chatterjee M.
    Cancer Res; 2007 Mar 15; 67(6):2881-92. PubMed ID: 17363612
    [Abstract] [Full Text] [Related]

  • 7. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model.
    Schreurs MW, Eggert AA, de Boer AJ, Vissers JL, van Hall T, Offringa R, Figdor CG, Adema GJ.
    Cancer Res; 2000 Dec 15; 60(24):6995-7001. PubMed ID: 11156402
    [Abstract] [Full Text] [Related]

  • 8. [Enhanced antitumor effects induced by lymphotactin gene-modified dendritic cells after pulsed with tumor antigen peptide].
    Zhang W, He L, Cao X.
    Zhonghua Yi Xue Za Zhi; 1999 Mar 15; 79(3):170-3. PubMed ID: 11601032
    [Abstract] [Full Text] [Related]

  • 9. Induction of protective CTL immunity against peptide transporter TAP-deficient tumors through dendritic cell vaccination.
    Chambers B, Grufman P, Fredriksson V, Andersson K, Roseboom M, Laban S, Camps M, Wolpert EZ, Wiertz EJ, Offringa R, Ljunggren HG, van Hall T.
    Cancer Res; 2007 Sep 15; 67(18):8450-5. PubMed ID: 17875682
    [Abstract] [Full Text] [Related]

  • 10. Protective antitumor immunity induced by immunization with completely allogeneic tumor cells.
    Toes RE, Blom RJ, van der Voort E, Offringa R, Melief CJ, Kast WM.
    Cancer Res; 1996 Aug 15; 56(16):3782-7. PubMed ID: 8706024
    [Abstract] [Full Text] [Related]

  • 11. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
    Liu Y, Saxena A, Zheng C, Carlsen S, Xiang J.
    J Gene Med; 2004 Aug 15; 6(8):857-68. PubMed ID: 15293344
    [Abstract] [Full Text] [Related]

  • 12. Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells.
    Sun JB, Eriksson K, Li BL, Lindblad M, Azem J, Holmgren J.
    Clin Immunol; 2004 Jul 15; 112(1):35-44. PubMed ID: 15207780
    [Abstract] [Full Text] [Related]

  • 13. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation.
    Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, van der Burg SH, Offringa R.
    Eur J Immunol; 2008 Apr 15; 38(4):1033-42. PubMed ID: 18350546
    [Abstract] [Full Text] [Related]

  • 14. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy.
    Diehl L, den Boer AT, Schoenberger SP, van der Voort EI, Schumacher TN, Melief CJ, Offringa R, Toes RE.
    Nat Med; 1999 Jul 15; 5(7):774-9. PubMed ID: 10395322
    [Abstract] [Full Text] [Related]

  • 15. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity.
    Cao X, Zhang W, He L, Xie Z, Ma S, Tao Q, Yu Y, Hamada H, Wang J.
    J Immunol; 1998 Dec 01; 161(11):6238-44. PubMed ID: 9834111
    [Abstract] [Full Text] [Related]

  • 16. Dendritic cell vaccination induces cross-reactive cytotoxic T lymphocytes specific for wild-type and natural variant human immunodeficiency virus type 1 epitopes in HLA-A*0201/Kb transgenic mice.
    Abdel-Motal UM, Friedline R, Poligone B, Pogue-Caley RR, Frelinger JA, Tisch R.
    Clin Immunol; 2001 Oct 01; 101(1):51-8. PubMed ID: 11580226
    [Abstract] [Full Text] [Related]

  • 17. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
    Liu Y, Huang H, Chen Z, Zong L, Xiang J.
    J Gene Med; 2003 Aug 01; 5(8):668-80. PubMed ID: 12898636
    [Abstract] [Full Text] [Related]

  • 18. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
    De Veerman M, Heirman C, Van Meirvenne S, Devos S, Corthals J, Moser M, Thielemans K.
    J Immunol; 1999 Jan 01; 162(1):144-51. PubMed ID: 9886380
    [Abstract] [Full Text] [Related]

  • 19. A strategy for efficient cross-presentation of CTL-epitope peptides leading to enhanced induction of in vivo tumor immunity.
    Hayashi A, Wakita H, Yoshikawa T, Nakanishi T, Tsutsumi Y, Mayumi T, Mukai Y, Yoshioka Y, Okada N, Nakagawa S.
    J Control Release; 2007 Jan 22; 117(1):11-9. PubMed ID: 17126444
    [Abstract] [Full Text] [Related]

  • 20. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
    Maitre N, Brown JM, Demcheva M, Kelley JR, Lockett MA, Vournakis J, Cole DJ.
    Clin Cancer Res; 1999 May 22; 5(5):1173-82. PubMed ID: 10353754
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.